Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival?

Julio Sandoval, Luis E. Santos, Julio Córdova, Tomás Pulido, Gerardo Gutiérrez, Edgar Bautista, Maria Luisa Martinez Guerra, Héctor Peña, Craig Broberg

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    Objective. To determine the impact of anticoagulation on survival in Eisenmenger syndrome. Background. The use of anticoagulation for primary prevention of adverse events in patients with Eisenmenger syndrome has been proposed but not studied. Strong arguments have been made both for and against anticoagulation based on the known risk of hemoptysis and pulmonary vascular thrombosis. Design and Setting. Retrospective cohort study at a tertiary referral hospital. Patients and Interventions. One hundred forty-four patients with established Eisenmenger physiology all underwent initial laboratory, echocardiographic, and catheterization evaluation after initial referral. We retrospectively identified patients who were started on anticoagulation (AC) and compared them to patients who did not receive anticoagulation therapy (non-AC). Baseline variables were compared between groups, as well as between survivors and nonsurvivors. Analyses of prognostic factors and survival were done using Cox and Kaplan-Meier methods. Outcome Measures. The primary outcome was death since time of baseline evaluation. Results. We identified 48 anticoagulated and 44 nonanticoagulated patients with Eisenmenger physiology (oxygen saturation 82±9%, PaO 2 48±8mmHg, hemoglobin 18.6±4g/dL). More atrial septal defect patients were in the AC group, but there were no other baseline differences in clinical, functional, or hemodynamic data. After mean follow-up of 7±5.4years (range 1-31), 11 patients died in the AC and 10 died in the non-AC group. There was no survival difference between groups (log rank test=1.78; P is not significant). For the entire cohort, mortality was significantly associated with New York Heart Association class 3-4 (hazard ratio=4.2), evidence of right heart failure (hazard ratio=13.6), and a mean corpuscular volume

    Original languageEnglish (US)
    Pages (from-to)268-276
    Number of pages9
    JournalCongenital Heart Disease
    Volume7
    Issue number3
    DOIs
    StatePublished - May 2012

    Fingerprint

    Eisenmenger Complex
    Survival
    Erythrocyte Indices
    Hemoptysis
    Atrial Heart Septal Defects
    Primary Prevention
    Survival Analysis
    Tertiary Care Centers
    Catheterization
    Blood Vessels
    Survivors
    Hemoglobins
    Thrombosis
    Cohort Studies
    Referral and Consultation
    Heart Failure
    Retrospective Studies
    Hemodynamics
    Outcome Assessment (Health Care)
    Oxygen

    Keywords

    • Anticoagulation
    • Cyanosis
    • Eisenmenger syndrome
    • Hemoptysis
    • Pulmonary arterial hypertension

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Pediatrics, Perinatology, and Child Health
    • Surgery
    • Radiology Nuclear Medicine and imaging

    Cite this

    Sandoval, J., Santos, L. E., Córdova, J., Pulido, T., Gutiérrez, G., Bautista, E., ... Broberg, C. (2012). Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival? Congenital Heart Disease, 7(3), 268-276. https://doi.org/10.1111/j.1747-0803.2012.00633.x

    Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival? / Sandoval, Julio; Santos, Luis E.; Córdova, Julio; Pulido, Tomás; Gutiérrez, Gerardo; Bautista, Edgar; Martinez Guerra, Maria Luisa; Peña, Héctor; Broberg, Craig.

    In: Congenital Heart Disease, Vol. 7, No. 3, 05.2012, p. 268-276.

    Research output: Contribution to journalArticle

    Sandoval, J, Santos, LE, Córdova, J, Pulido, T, Gutiérrez, G, Bautista, E, Martinez Guerra, ML, Peña, H & Broberg, C 2012, 'Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival?', Congenital Heart Disease, vol. 7, no. 3, pp. 268-276. https://doi.org/10.1111/j.1747-0803.2012.00633.x
    Sandoval J, Santos LE, Córdova J, Pulido T, Gutiérrez G, Bautista E et al. Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival? Congenital Heart Disease. 2012 May;7(3):268-276. https://doi.org/10.1111/j.1747-0803.2012.00633.x
    Sandoval, Julio ; Santos, Luis E. ; Córdova, Julio ; Pulido, Tomás ; Gutiérrez, Gerardo ; Bautista, Edgar ; Martinez Guerra, Maria Luisa ; Peña, Héctor ; Broberg, Craig. / Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival?. In: Congenital Heart Disease. 2012 ; Vol. 7, No. 3. pp. 268-276.
    @article{4f54a6ea11294786a47c1af5efec66bf,
    title = "Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival?",
    abstract = "Objective. To determine the impact of anticoagulation on survival in Eisenmenger syndrome. Background. The use of anticoagulation for primary prevention of adverse events in patients with Eisenmenger syndrome has been proposed but not studied. Strong arguments have been made both for and against anticoagulation based on the known risk of hemoptysis and pulmonary vascular thrombosis. Design and Setting. Retrospective cohort study at a tertiary referral hospital. Patients and Interventions. One hundred forty-four patients with established Eisenmenger physiology all underwent initial laboratory, echocardiographic, and catheterization evaluation after initial referral. We retrospectively identified patients who were started on anticoagulation (AC) and compared them to patients who did not receive anticoagulation therapy (non-AC). Baseline variables were compared between groups, as well as between survivors and nonsurvivors. Analyses of prognostic factors and survival were done using Cox and Kaplan-Meier methods. Outcome Measures. The primary outcome was death since time of baseline evaluation. Results. We identified 48 anticoagulated and 44 nonanticoagulated patients with Eisenmenger physiology (oxygen saturation 82±9{\%}, PaO 2 48±8mmHg, hemoglobin 18.6±4g/dL). More atrial septal defect patients were in the AC group, but there were no other baseline differences in clinical, functional, or hemodynamic data. After mean follow-up of 7±5.4years (range 1-31), 11 patients died in the AC and 10 died in the non-AC group. There was no survival difference between groups (log rank test=1.78; P is not significant). For the entire cohort, mortality was significantly associated with New York Heart Association class 3-4 (hazard ratio=4.2), evidence of right heart failure (hazard ratio=13.6), and a mean corpuscular volume",
    keywords = "Anticoagulation, Cyanosis, Eisenmenger syndrome, Hemoptysis, Pulmonary arterial hypertension",
    author = "Julio Sandoval and Santos, {Luis E.} and Julio C{\'o}rdova and Tom{\'a}s Pulido and Gerardo Guti{\'e}rrez and Edgar Bautista and {Martinez Guerra}, {Maria Luisa} and H{\'e}ctor Pe{\~n}a and Craig Broberg",
    year = "2012",
    month = "5",
    doi = "10.1111/j.1747-0803.2012.00633.x",
    language = "English (US)",
    volume = "7",
    pages = "268--276",
    journal = "Congenital Heart Disease",
    issn = "1747-079X",
    publisher = "Wiley-Blackwell",
    number = "3",

    }

    TY - JOUR

    T1 - Does Anticoagulation in Eisenmenger Syndrome Impact Long-term Survival?

    AU - Sandoval, Julio

    AU - Santos, Luis E.

    AU - Córdova, Julio

    AU - Pulido, Tomás

    AU - Gutiérrez, Gerardo

    AU - Bautista, Edgar

    AU - Martinez Guerra, Maria Luisa

    AU - Peña, Héctor

    AU - Broberg, Craig

    PY - 2012/5

    Y1 - 2012/5

    N2 - Objective. To determine the impact of anticoagulation on survival in Eisenmenger syndrome. Background. The use of anticoagulation for primary prevention of adverse events in patients with Eisenmenger syndrome has been proposed but not studied. Strong arguments have been made both for and against anticoagulation based on the known risk of hemoptysis and pulmonary vascular thrombosis. Design and Setting. Retrospective cohort study at a tertiary referral hospital. Patients and Interventions. One hundred forty-four patients with established Eisenmenger physiology all underwent initial laboratory, echocardiographic, and catheterization evaluation after initial referral. We retrospectively identified patients who were started on anticoagulation (AC) and compared them to patients who did not receive anticoagulation therapy (non-AC). Baseline variables were compared between groups, as well as between survivors and nonsurvivors. Analyses of prognostic factors and survival were done using Cox and Kaplan-Meier methods. Outcome Measures. The primary outcome was death since time of baseline evaluation. Results. We identified 48 anticoagulated and 44 nonanticoagulated patients with Eisenmenger physiology (oxygen saturation 82±9%, PaO 2 48±8mmHg, hemoglobin 18.6±4g/dL). More atrial septal defect patients were in the AC group, but there were no other baseline differences in clinical, functional, or hemodynamic data. After mean follow-up of 7±5.4years (range 1-31), 11 patients died in the AC and 10 died in the non-AC group. There was no survival difference between groups (log rank test=1.78; P is not significant). For the entire cohort, mortality was significantly associated with New York Heart Association class 3-4 (hazard ratio=4.2), evidence of right heart failure (hazard ratio=13.6), and a mean corpuscular volume

    AB - Objective. To determine the impact of anticoagulation on survival in Eisenmenger syndrome. Background. The use of anticoagulation for primary prevention of adverse events in patients with Eisenmenger syndrome has been proposed but not studied. Strong arguments have been made both for and against anticoagulation based on the known risk of hemoptysis and pulmonary vascular thrombosis. Design and Setting. Retrospective cohort study at a tertiary referral hospital. Patients and Interventions. One hundred forty-four patients with established Eisenmenger physiology all underwent initial laboratory, echocardiographic, and catheterization evaluation after initial referral. We retrospectively identified patients who were started on anticoagulation (AC) and compared them to patients who did not receive anticoagulation therapy (non-AC). Baseline variables were compared between groups, as well as between survivors and nonsurvivors. Analyses of prognostic factors and survival were done using Cox and Kaplan-Meier methods. Outcome Measures. The primary outcome was death since time of baseline evaluation. Results. We identified 48 anticoagulated and 44 nonanticoagulated patients with Eisenmenger physiology (oxygen saturation 82±9%, PaO 2 48±8mmHg, hemoglobin 18.6±4g/dL). More atrial septal defect patients were in the AC group, but there were no other baseline differences in clinical, functional, or hemodynamic data. After mean follow-up of 7±5.4years (range 1-31), 11 patients died in the AC and 10 died in the non-AC group. There was no survival difference between groups (log rank test=1.78; P is not significant). For the entire cohort, mortality was significantly associated with New York Heart Association class 3-4 (hazard ratio=4.2), evidence of right heart failure (hazard ratio=13.6), and a mean corpuscular volume

    KW - Anticoagulation

    KW - Cyanosis

    KW - Eisenmenger syndrome

    KW - Hemoptysis

    KW - Pulmonary arterial hypertension

    UR - http://www.scopus.com/inward/record.url?scp=84861543298&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84861543298&partnerID=8YFLogxK

    U2 - 10.1111/j.1747-0803.2012.00633.x

    DO - 10.1111/j.1747-0803.2012.00633.x

    M3 - Article

    C2 - 22360787

    AN - SCOPUS:84861543298

    VL - 7

    SP - 268

    EP - 276

    JO - Congenital Heart Disease

    JF - Congenital Heart Disease

    SN - 1747-079X

    IS - 3

    ER -